The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type
The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type
复制标题
DOI：
10.1007/bf02246578
复制
发表时间：
1996-02-01
影响因子：
3.4
通讯作者：
Hodges, JR
中科院分区：
文献类型：
--
作者：
Coull, JT;Sahakian, BJ;Hodges, JR
我们以前已经证明，混合的α（1）/α（2）肾上腺素受体激动剂可乐定会损害健康志愿者的某些注意力和执行功能。本研究探讨α 2肾上腺素受体拮抗剂咪唑克生（IDZ）对额叶型痴呆（DFT）患者认知功能的影响。使用安慰剂对照的ABBA设计，三名DFT患者接受了两剂IDZ，并进行了一系列计算机化的注意力、记忆力和执行功能测试。研究发现，咪唑克生可以产生剂量依赖性的表现改善，特别是在计划，持续注意力，语言流畅性和情景记忆的测试中。相比之下，IDZ在空间工作记忆测试中表现出缺陷。这些结果表明，IDZ可能是有用的，作为一个假定的认知增强剂，特别是在患者表现出特定模式的额叶功能障碍。
The mixed alpha(1)/alpha(2) adrenoceptor agonist clonidine has been shown by us previously to impair certain attentional and executive functions in healthy volunteers. The present investigation examines the effects of the alpha(2) adrenoceptor antagonist idazoxan (IDZ) on cognitive function in patients with dementia of frontal type (DFT). Using a placebo-controlled ABBA design, three DFT patients were given two doses of IDZ and tested on a range of computerised tests of attention, memory and executive function. Idazoxan was found to produce dose-dependent improvements in performance, particularly on tests of planning, sustained attention, verbal fluency and episodic memory. In contrast, IDZ produced deficits in performance on a test of spatial working memory. These results suggest that IDZ may be useful as a putative cognitive enhancer, particularly in patients showing a specific pattern of frontal lobe dysfunction.